Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 Alpha Tau (Nasdaq: DRTS) announced acceptance of the first-ever oral presentation of Alpha DaRT pancreatic cancer clinical results at Digestive Disease Week (DDW) 2026.The abstract, “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” will be presented May 2, 2026 at 10:30am Central by Dr. Harold Jacob, using combined data from two Hadassah Medical Center protocols. According to the company, these foundational studies informed the IMPACT pilot now enrolling in the U.S. and ongoing planning toward a future pivotal study.

#DRTS #DRTSW Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update Alpha Tau (NASDAQ: DRTS) reported full-year 2025 results and a corporate update highlighting regulatory, clinical and manufacturing progress. Key items: $76.9M cash, Japanese marketing approval for head and neck cancer, five parallel U.S. trial approvals, positive pancreatic data (ORR 22%/DCR 81%), and a commercial-scale New Hampshire license.The company reported a $42.6M net loss for 2025 and outlined upcoming recruitment and safety readouts through 2026.

#DRTS #DRTSW Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of

#DRTS #DRTSW Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

www.stocktitan.net/news/DRTS/alpha-tau-succ...

Alpha Tau (NASDAQ: DRTS) to share Alpha DaRT pancreatic cancer data at 2026 ASCO GI Alpha Tau’s Alpha DaRT tech will be featured in two pancreatic cancer abstracts at 2026 ASCO GI, as a Montreal pilot study and a 30-patient U.S. trial advance.

#DRTS #DRTSW Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer Alpha Tau (NASDAQ: DRTS) announced that the FDA approved an Investigational Device Exemption (IDE) to start a pilot study of Alpha DaRT for patients with locally recurrent prostate cancer on Dec 2, 2025. The IDE is Alpha Tau’s fifth active U.S. IDE and the U.S. trial will enroll up to 12 patients meeting biochemical recurrence by the Phoenix definition (PSA rise ≥2 ng/mL from nadir).The study’s primary objective is to evaluate safety; secondary objectives include biochemical and clinical progression and overall survival. Management positions Alpha DaRT as a focused local salvage alpha-radiation option to potentially replace systemic androgen deprivation therapy for recurrent prostate cancer.

#DRTS #DRTSW Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

www.stocktitan.net/news/DRTS/alpha-tau-rece...

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study - - Newly received r adioactive m aterial l icense for New Hampshire f acility positions the Company for continued advancement t owards commercial readiness - - Multiple meaningful milestones targeted in

#DRTS #DRTSW Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Alpha Tau (Nasdaq: DRTS) receives NH radioactive material license, targets 2026 output License clears Alpha Tau’s Hudson, NH plant to equip, validate, and add thorium generators. Phase 1 capacity ~400,000 Alpha DaRT sources; production aimed in 2026.

#DRTS #DRTSW Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

www.stocktitan.net/news/DRTS/alpha-tau-anno...

87% of Pancreatic Cancer Patients Could Benefit: Alpha Tau Launches Groundbreaking Radiation Trial Alpha Tau initiates IMPACT trial combining Alpha DaRT therapy with chemotherapy for inoperable pancreatic cancer. Study targets 66,000 annual U.S. cases with 87% deemed inoperable at diagnosis.

#DRTS #DRTSW Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

www.stocktitan.net/news/DRTS/alpha-tau-succ...

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, reported Q2 2025 financial results and corporate updates. The company received FDA approval for an IDE to conduct a U.S. pilot study for recurrent glioblastoma multiforme (GBM) treatment. Alpha Tau secured $36.9 million through strategic equity offering from Oramed and maintains a strong cash position of $83.3 million.The company is advancing multiple U.S. clinical trials, including studies in pancreatic cancer and GBM, with patient treatments expected to begin in 2025. Their ReSTART pivotal skin cancer trial is nearing completion. The company's first phase of their Hudson, NH commercial facility is expected to be operational by early 2026. For H1 2025, Alpha Tau reported a net loss of $18.8 million ($0.25 per share), compared to $15.4 million ($0.22 per share) in H1 2024.

#DRTS #DRTSW Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update Alpha Tau Medical (NASDAQ: DRTS) reported Q1 2025 financial results and significant clinical progress for its Alpha DaRT® cancer therapy. Key highlights include impressive interim results from pancreatic cancer trials with >90% disease control rate and positive safety profile. A combination trial with Keytruda® in head and neck cancer showed 75% systemic objective response rate and 37.5% complete response rate. The FDA approved IDEs for U.S. pilot studies in pancreatic cancer and glioblastoma. The company secured MDSAP certification for its Jerusalem facility and completed a $36.9 million financing with Oramed Pharmaceuticals. Financial results showed a net loss of $8.7 million ($0.12 per share) with cash position of $54.8 million as of March 31, 2025, further strengthened by the April financing.

#DRTS #DRTSW Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials Alpha Tau's Alpha DaRT technology progresses with FDA trial approval for aggressive brain cancer. Breakthrough device targets untreatable glioblastoma. See trial details.

#DRTS #DRTSW Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

www.stocktitan.net/news/DRTS/alpha-tau-rece...

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update Alpha Tau Medical (NASDAQ: DRTS) reported its full year 2024 financial results and corporate updates. The company's innovative Alpha DaRT cancer therapy showed promising interim results across multiple trials:Key clinical highlights include high disease control rates in pancreatic cancer trials, and impressive response rates in combination with Keytruda for head and neck cancer treatment. The company received FDA approval for a U.S. pilot study combining Alpha DaRT with first-line chemotherapy for pancreatic cancer patients.Financial results show: R&D expenses: $27.0M (vs $26.4M in 2023)Net loss: $31.8M or $0.45 per share (vs $29.2M in 2023)Cash position: $62.9M (vs $84.9M in 2023)The company expects its current cash balance to fund operations for at least two years.

#DRTS #DRTSW Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-anno...

Can This New Medical Certification Transform Alpha Tau's Cancer Treatment Rollout? Strategic certification streamlines Alpha DaRT therapy's path to five major markets, accelerating global commercialization of innovative alpha-radiation cancer treatment.

#DRTS #DRTSW Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

www.stocktitan.net/news/DRTS/alpha-tau-rece...

Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials Alpha DaRT therapy achieves 100% delivery success in pancreatic cancer trials and 75% response rate in head & neck cancer, with new FDA-approved study launching

#DRTS #DRTSW Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

www.stocktitan.net/news/DRTS/alpha-tau-anno...

#DRTS #DRTSW Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/DRTS/alpha-tau-medi...